Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2714989 | 0.98 | LOXL2 (0.38) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15350734 | 0.88 | NUDT1 (0.38) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16759447 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15350541 | 0.85 | SCN9A (0.46) | SMN1; SMN2MRGPRX4SCN9AAAK1 | |
| SCHEMBL2714774 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15599157 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4550308 | 0.82 | LOXL2 (0.38) | LOXL2ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL2714225 | 0.82 | AAK1 (0.38) | LOXL2ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL23159359 | 0.81 | MRGPRX4 (0.38) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16770601 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2MRGPRX4CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9187475-B2 | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2841435-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, SCN1B, SCN1A | SMN1; SMN2 338/4885MRGPRX4 2360/4885CYP1A2 3556/4885 |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | SMN1; SMN2 598/4885MRGPRX4 950/4885CYP1A2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.